The NCDR Left Atrial Appendage Occlusion Registry.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
07 04 2020
Historique:
received: 30 05 2019
revised: 31 10 2019
accepted: 09 12 2019
pubmed: 3 4 2020
medline: 22 12 2020
entrez: 3 4 2020
Statut: ppublish

Résumé

Left atrial appendage occlusion (LAAO) to prevent stroke in patients with atrial fibrillation has been evaluated in 2 randomized trials; post-approval clinical data are limited. The purpose of this study was to describe the National Cardiovascular Data Registry (NCDR) LAAO Registry and present patient, hospital, and physician characteristics and in-hospital adverse event rates for Watchman procedures in the United States during its first 3 years. The authors describe the LAAO Registry structure and governance, the outcome adjudication processes, and the data quality and collection processes. They characterize the patient population, performing hospitals, and in-hospital adverse event rates. A total of 38,158 procedures from 495 hospitals performed by 1,318 physicians in the United States were included between January 2016 and December 2018. The mean patient age was 76.1 ± 8.1 years, the mean CHA The LAAO Registry has enrolled >38,000 patients implanted with the device. Patients were generally older with more comorbidities than those enrolled in the pivotal trials; however, major in-hospital adverse event rates were lower than reported in those trials.

Sections du résumé

BACKGROUND
Left atrial appendage occlusion (LAAO) to prevent stroke in patients with atrial fibrillation has been evaluated in 2 randomized trials; post-approval clinical data are limited.
OBJECTIVES
The purpose of this study was to describe the National Cardiovascular Data Registry (NCDR) LAAO Registry and present patient, hospital, and physician characteristics and in-hospital adverse event rates for Watchman procedures in the United States during its first 3 years.
METHODS
The authors describe the LAAO Registry structure and governance, the outcome adjudication processes, and the data quality and collection processes. They characterize the patient population, performing hospitals, and in-hospital adverse event rates.
RESULTS
A total of 38,158 procedures from 495 hospitals performed by 1,318 physicians in the United States were included between January 2016 and December 2018. The mean patient age was 76.1 ± 8.1 years, the mean CHA
CONCLUSIONS
The LAAO Registry has enrolled >38,000 patients implanted with the device. Patients were generally older with more comorbidities than those enrolled in the pivotal trials; however, major in-hospital adverse event rates were lower than reported in those trials.

Identifiants

pubmed: 32238316
pii: S0735-1097(20)30089-9
doi: 10.1016/j.jacc.2019.12.040
pmc: PMC7205034
mid: NIHMS1569022
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1503-1518

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL142765
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL142765
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Références

Heart Rhythm. 2017 Sep;14(9):1302-1308
pubmed: 28577840
Am Heart J. 2015 Dec;170(6):1184-94
pubmed: 26678640
J Am Coll Cardiol. 1995 Feb;25(2):452-9
pubmed: 7829800
J Am Coll Cardiol. 2017 Jan 24;69(3):253-261
pubmed: 27816552
Eur Heart J. 2016 Aug;37(31):2465-74
pubmed: 26822918
Heart. 2011 May;97(9):762-5
pubmed: 21378010
N Engl J Med. 2010 Nov 4;363(19):1875-6
pubmed: 21047252
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132
pubmed: 30703431
J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975
pubmed: 29103847
Am J Cardiol. 2015 Feb 1;115(3):378-84
pubmed: 25579887
Lancet. 1994 Mar 19;343(8899):687-91
pubmed: 7907677
Circulation. 1998 Sep 8;98(10):946-52
pubmed: 9737513
Int J Cardiol Heart Vasc. 2019 Apr 09;23:100358
pubmed: 31008181
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Catheter Cardiovasc Interv. 2016 Mar;87(4):787-94
pubmed: 26354821
Arch Intern Med. 1987 Sep;147(9):1561-4
pubmed: 3632164
Circulation. 2006 Jul 11;114(2):119-25
pubmed: 16818816
Europace. 2017 Jan;19(1):4-15
pubmed: 27540038
Ann Thorac Surg. 1996 Feb;61(2):755-9
pubmed: 8572814
Lancet. 2009 Aug 15;374(9689):534-42
pubmed: 19683639
J Am Coll Cardiol. 2015 Jun 23;65(24):2614-2623
pubmed: 26088300
JACC Cardiovasc Interv. 2009 Jul;2(7):594-600
pubmed: 19628179
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
J Am Coll Cardiol. 2013 Jul 9;62(2):108-118
pubmed: 23062528
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
JAMA. 2001 May 9;285(18):2370-5
pubmed: 11343485
J Am Coll Cardiol. 2017 Mar 21;69(11):1427-1450
pubmed: 28025065
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Am Heart J. 2019 May;211:45-53
pubmed: 30831333
JAMA. 2014 Nov 19;312(19):1988-98
pubmed: 25399274
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
J Am Coll Cardiol. 2012 Oct 16;60(16):1484-8
pubmed: 22999725
J Am Coll Cardiol. 2014 Jul 8;64(1):1-12
pubmed: 24998121
Am Heart J. 2006 Oct;152(4):720-3
pubmed: 16996847
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Heart Rhythm. 2011 Feb;8(2):188-93
pubmed: 21050893

Auteurs

James V Freeman (JV)

Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut. Electronic address: james.freeman@yale.edu.

Paul Varosy (P)

Division of Cardiology, University of Colorado School of Medicine, Denver, Colorado.

Matthew J Price (MJ)

Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California.

David Slotwiner (D)

Division of Cardiology, New York Presbyterian Queens, Weill Cornell Medical College, New York, New York.

Fred M Kusumoto (FM)

Department of Cardiovascular Disease, Mayo Clinic, Jacksonville, Florida.

Chidambaram Rammohan (C)

Division of Cardiovascular Medicine, Palo Alto Medical Foundation, El Camino Hospital, Mountain View, California.

Clifford J Kavinsky (CJ)

Division of Cardiovascular Medicine, Rush University Medical Center, Chicago, Illinois.

Zoltan G Turi (ZG)

Center for Structural and Congenital Heart Disease, Hackensack University Medical Center, Hackensack, New Jersey.

Joseph Akar (J)

Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.

Cristina Koutras (C)

American College of Cardiology Foundation, Washington, DC.

Jeptha P Curtis (JP)

Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.

Frederick A Masoudi (FA)

Division of Cardiology, University of Colorado School of Medicine, Denver, Colorado.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH